Clinical Trial Update: The Efficacy and Safety of Secukinumab in Patients With Ichthyoses [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of secukinumab in patients with ichthyoses has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Congenital Ichthyosis
• Congenital Ichthyosiform Erythroderma
• Epidermolytic Ichthyosis
• Ichthyosis
• Lamellar Ichthyosis
• Netherton Syndrome

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Northwestern University | Conditions: Ichthyosis, Autosomal Recessive Congenital Ichthyosis | Phase 2 | Status: COMPLETED | Results posted: 2021-08-25